Welcome to our dedicated page for Pmv Pharmaceuticals news (Ticker: PMVP), a resource for investors and traders seeking the latest updates and insights on Pmv Pharmaceuticals stock.
PMV Pharmaceuticals, Inc. (PMVP) is a clinical-stage biopharmaceutical company pioneering precision oncology therapies targeting p53 mutations, a key driver in many cancers. This page provides investors and researchers with verified updates on clinical trials, regulatory milestones, and corporate developments.
Access real-time announcements including phase progressions for PC14586 and other pipeline candidates, financial disclosures, and strategic collaborations. Our curated repository ensures you stay informed about PMVP’s tumor-agnostic approach to reactivating p53’s tumor-suppressing function.
Key updates cover clinical data publications, FDA designations, and research partnerships advancing small-molecule therapeutics. Bookmark this page for streamlined access to PMVP’s progress in developing treatments that address unmet needs in genetically defined cancers.
PMV Pharmaceuticals (Nasdaq: PMVP) announced that its CEO, David H. Mack, Ph.D., will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 PM ET. The company is known for its innovative work in precision oncology, focusing on small molecule therapies targeting p53 mutants, which are implicated in nearly half of all cancers. PMV Pharma aims to revolutionize cancer treatment through its unique insights into p53 biology, established by co-founder Dr. Arnold Levine in 1979.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported its Q2 2021 financial results, ending the quarter with $339.0 million in cash, down from $361.4 million at year-end 2020. The net loss for the six months was $24.5 million, up from $15.2 million in the same period last year. R&D expenses rose to $15.2 million, primarily due to increased clinical costs for the lead drug PC14586. Meanwhile, G&A expenses surged to $9.6 million, reflecting infrastructure costs for public operations. The company continues to enroll patients in its Phase 1/2 trial for PC14586, which targets p53 mutants in advanced solid tumors.
PMV Pharmaceuticals (Nasdaq: PMVP) announced its participation in the Bank of America Securities 2021 Napa Biopharma Virtual Conference, where David H. Mack, Ph.D., President & CEO, will present on June 14, 2021, at 2:30 PM ET. The company specializes in developing tumor-agnostic therapies targeting p53 mutations, prevalent in nearly half of all cancers. PMV Pharma combines over 40 years of p53 biology expertise with a strong pharmaceutical development focus. For more information, visit pmvpharma.com.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) announced that its CEO, David H. Mack, will present at the Goldman Sachs Annual Global Healthcare Conference on June 9, 2021, at 5:30 PM ET. The company, focused on developing small molecule, tumor-agnostic therapies targeting p53 mutants, invites investors to participate in one-on-one meetings during the event. Further details, including a link to the webcast, are provided in the release. PMV Pharma is headquartered in Cranbury, New Jersey, and utilizes over four decades of p53 biology research to advance its therapies.
PMV Pharmaceuticals, Inc. (PMVP) reported promising preclinical data on its investigational drug PC14586 at the AACR Annual Meeting 2021. This tumor-agnostic small molecule targets p53 mutations, with enrollment in its Phase 1/2 trial proceeding as planned. Financial results for Q1 2021 reveal a net loss of $11.6 million and operational cash usage of $12.9 million. Cash reserves decreased to $348.4 million from $361.4 million. The company also expanded its Board and Scientific Advisory Board with leading experts in precision oncology.
PMV Pharmaceuticals (Nasdaq: PMVP) announced that CEO David H. Mack, Ph.D., will present at the Bank of America Healthcare Conference on May 13, 2021, at 12:30 PM ET. The presentation will discuss PMV's pioneering work in precision oncology and its focus on developing small molecule therapies targeting p53 mutants, which are prevalent in about half of all cancers. The company will also engage in one-on-one meetings with investors during the conference. A replay of the presentation will be accessible on PMV's website.
PMV Pharmaceuticals presents promising preclinical data on PC14586, a small molecule p53 reactivator targeting the Y220C mutation. The drug demonstrated robust tumor regression in mouse models with once daily oral dosing. Notably, PC14586 selectively stabilizes the p53 Y220C mutant, restoring its activity without affecting wild-type or other mutant forms. Enrollment is ongoing for a Phase 1/2 clinical trial in patients with advanced solid tumors featuring this specific mutation, with pharmacodynamic biomarkers developed for future clinical use.
PMV Pharmaceuticals (Nasdaq: PMVP) announced the appointment of Charles M. Baum, M.D., Ph.D., to its Board of Directors. Dr. Baum is recognized for his contributions to precision oncology, with a strong track record in developing oncology portfolios. CEO David Mack expressed optimism about Baum's expertise enhancing their lead candidate, PC14856, a p53 reactivator. Dr. Baum's experience includes leadership roles at Mirati Therapeutics and Pfizer, where he developed key oncology drugs. PMV focuses on therapies targeting p53 mutations, pivotal in cancer treatment.
PMV Pharmaceuticals announced its participation at the AACR Annual Meeting 2021 from April 10-15, where it will present on PC14586, the first orally bioavailable small molecule reactivator of the Y220C mutant p53. This therapy targets a significant mutation found in various cancers, aiming to restore the tumor suppressor function of p53. Details of the presentation include the title, authors, and timing. PMV aims to develop this innovative treatment for patients with advanced solid tumors.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) has initiated a Phase 1/2 study of PC14586, targeting advanced solid tumors with a p53 Y220C mutation. The FDA granted Fast Track designation for this investigational therapy. Financially, the company reported a net loss of $34.4 million for 2020, up from $25.4 million in 2019. PMVP ended Q4 2020 with $361.4 million in cash, a significant increase from $101.5 million a year earlier. R&D expenses rose to $23.9 million due to clinical advances, while G&A expenses increased to $11 million as the company expands its public operations.
